Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

HBO After Thrombectomy for AIS With LVO

2 juni 2026 uppdaterad av: Beijing Tiantan Hospital

HyperBaric Oxygen Therapy After ACute Thrombectomy in Acute Ischemic strOke Due to Large Vessel occlusioN

The purpose of this RCT trial is to evaluate whether the sequential hyperbaric oxygen therapy can improve the 90-day functional outcome in patients with acute large vessel occlusion ischemic stroke after endovascular treatment.

Studieöversikt

Detaljerad beskrivning

This is a multicenter, prospective, open-label, endpoint-blinded, randomized controlled trial with a 1:1 ratio, comparing the effect of hyperbaric oxygen therapy plus standard medical treatment versus standard medical treatment alone after endovascular treatment in patients with acute large vessel occlusion ischemic stroke. The primary outcome is modified Rankin Scale (mRS) score distribution at 90 days (±14 days) after randomization.

Studietyp

Interventionell

Inskrivning (Beräknad)

420

Fas

  • Inte tillämpbar

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studiekontakt

Studieorter

    • Beijing Municipality
      • Beijing, Beijing Municipality, Kina, 100071
        • Rekrytering
        • Beijing Tiantan Hospital
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Vuxen
  • Äldre vuxen

Tar emot friska volontärer

Nej

Beskrivning

Inclusion Criteria:

  1. Age 18~80 years;
  2. Clinically diagnosed as acute large vessel occlusive ischemic stroke, suitable for and received endovascular treatment according to current clinical guidelines;
  3. The onset of stroke or the last normal time to the time of endovascular treatment ≤ 24 hours;
  4. Pre-stroke mRS score of 0 or 1;
  5. Baseline NIHSS score before endovascular treatment ≥ 6 points in the anterior circulation or ≥10 points in the posterior circulation;
  6. CTA, MRA, or DSA angiography before endovascular treatment confirmed occlusion of large vessels (internal carotid artery, middle cerebral artery M1 segment, basilar artery), consistent with symptoms and signs;
  7. The corresponding anterior circulation ASPECTS score or posterior circulation pc-ASPECTS score ≥ 6 points;
  8. The pontine midbrain index (PMI) of patients with acute basilar artery occlusion ≤3;
  9. Patients or their family members sign the informed consent form.

Exclusion Criteria:

  1. Patients with extensive bleeding or severe increase in infarct area, midline displacement (>0.5cm), etc. during endovascular treatment, who plan to undergo bone valve decompression or ventricular drainage;
  2. Known bleeding risk factors, including coagulation factor deficiency, or receiving anticoagulant therapy, INR>3.0 or APTT > 3 times normal or platelet count less than 50×10⁹/L;
  3. Severe hepatic or renal dysfunction (severe hepatic dysfunction refers to ALT or AST > 3 times the upper limit of the normal range, severe renal dysfunction refers to serum creatinine Cr >1.5 times the upper limit of the normal range);
  4. Females of pregnancy, or positive pregnancy test prior to randomization;
  5. Severe persistent and medication-uncontrollable hypertension (systolic blood > 185 mmHg or diastolic blood > 110 mmHg)
  6. Baseline blood glucose of <50 mg/dL (2.78 mmol/L) or >400 mg/dL (22.20 mmol/L);
  7. The oxygen required to maintain 95% of peripheral arterial oxygen saturation (SaO2) under the current medium-term management guidelines > 3L/min;
  8. End-stage disease other than the nervous system, life expectancy < 90 days;
  9. Participating in other drug or medical device clinical trials;
  10. CT or MR suggests intracranial tumors (other than meningiomas) or other high-risk intracranial vascular malformations;
  11. Patients with anemia, polycythemia or other conditions requiring urgent oxygen;
  12. Unable to cooperate with hyperbaric oxygen therapy, or have other diseases that are not suitable for hyperbaric oxygen therapy (such as active/chronic obstructive pulmonary disease, acute respiratory distress syndrome, tension pneumothorax, tension pneumocephalus, etc.).

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Enda

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Aktiv komparator: Standard medicinsk behandling
According to the current guideline "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association" "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023", they receive standard medical treatment and monitoring (including antithrombotic drugs, lipid-lowering drugs, blood pressure management, etc.), not entering the hyperbaric oxygen chamber for treatment.
Andra namn:
  • medicinsk vård
Experimentell: Hyperbaric oxygen therapy+ standard medical treatment

The first treatment was initiated within 24 hours after enrollment. The treatment plan is: in a medical multi-person air pressurized chamber, the treatment pressure is 0.2 MPa, the pressurization time is 30 minutes, the mask inhales 100% oxygen for 60 minutes, and the decompression time is 30 minutes. Once a day, once on the 1st, 2nd, and 3rd days after enrollment (i.e., within the 24-hour, 48-hour, and 72-hour time window), a total of 3 times. Vital signs such as blood pressure, heart rate, and blood oxygen saturation will be monitored before, during, and after each hyperbaric oxygen therapy.

The rest of the treatment is standard medical treatment and monitoring according to the current clinical guideline "2026 Guideline for the Early Management of Patients With Acute Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association" "Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2023".

Andra namn:
  • HBO

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
mRS score distribution at 90 days
Tidsram: 90±14 days after randomization
Modified Rankin Scale (mRS) score distribution at 90 days (±14 days) after randomization
90±14 days after randomization

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
mRS score 0-1 at 90 days after randomization
Tidsram: 90±14 days after randomization
90±14 days after randomization
mRS score 0-2 at 90 days after randomization
Tidsram: 90±14 days after randomization
90±14 days after randomization
Change in NIHSS score from baseline to 24 hours postoperatively
Tidsram: 24 hours after endovascular treatment
24 hours after endovascular treatment
Change in NIHSS score from baseline to 5 days postoperatively (after the end of hyperbaric oxygen therapy)
Tidsram: 5 days after endovascular treatment
5 days after endovascular treatment
Recanalization rate of responsible arteries at 24-48h postoperatively
Tidsram: 24-48 hours after endovascular treatment
24-48 hours after endovascular treatment
Volume of cerebral infarction on the 5th postoperative day or at discharge (after the end of hyperbaric oxygen therapy)
Tidsram: 5 days after endovascular treatment or at discharge
assessed by MRI or CT
5 days after endovascular treatment or at discharge
Total number of days in hospital
Tidsram: From date of randomization until date of hospital discharge, assessed up to 30 days.
Number of days hospitalized (from randomization to hospital discharge)
From date of randomization until date of hospital discharge, assessed up to 30 days.
Quality of life EQ-5D-5L score at 90 days after randomization
Tidsram: 90±14 days after randomization
The EuroQoL 5-Dimensions 5-Level (EQ-5D-5L) is a five-dimension, five-level health-related quality of life instrument. Based on the Chinese value set, its utility score ranges from -0.391 to 1.000, with higher scores indicating better outcomes.
90±14 days after randomization
mRS score 0-1 at 1 year after randomization
Tidsram: 1 year ±30 days after randomization
1 year ±30 days after randomization
mRS score 0-2 at 1 year after randomization
Tidsram: 1 year ±30 days after randomization
1 year ±30 days after randomization

Andra resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
All-cause death 90 days after randomization
Tidsram: 90±14 days after randomization
90±14 days after randomization
Symptomatic intracranial hemorrhage at 18-36 hours after randomization
Tidsram: 18-36 hours after randomization
Symptomatic intracranial hemorrhage was defined according to the Heidelberg classification of hemorrhage
18-36 hours after randomization
Any type of intracranial hemorrhage at 18-36 hours after randomization
Tidsram: 18-36 hours after randomization
confirmed by CT or MRI images
18-36 hours after randomization

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Utredare

  • Huvudutredare: Ning Ma, MD, Beijing Tiantan Hospital
  • Huvudutredare: Qiuhong Yu, MD, Beijing Tiantan Hospital
  • Huvudutredare: Yuesong Pan, MD, Beijing Tiantan Hospital

Publikationer och användbara länkar

Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.

Allmänna publikationer

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Beräknad)

1 juni 2026

Primärt slutförande (Beräknad)

1 september 2027

Avslutad studie (Beräknad)

1 oktober 2027

Studieregistreringsdatum

Först inskickad

18 maj 2026

Först inskickad som uppfyllde QC-kriterierna

2 juni 2026

Första postat (Faktisk)

4 juni 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

4 juni 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

2 juni 2026

Senast verifierad

1 maj 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

NEJ

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera